EMEA-001429-PIP01-13-M06
Table of contents
Key facts
Invented name |
Besponsa
|
Active substance |
Inotuzumab ozogamicin
|
Therapeutic area |
|
Decision number |
P/0398/2022
|
PIP number |
EMEA-001429-PIP01-13-M06
|
Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of B cell acute lymphoblastic leukaemia
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 1304 6466 07 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|